Six male and two female subjects participated in a clinical study to determine the time course, the cumulative excretion, the intrasubject variability, the influence of site application, and the concentrations of codeine or phenobarbital in sweat following administration of a single dose of the drug. The doses of codeine and phenobarbital were 90 and 100 rag, respectively. Sweat was collected by means of a Sudormed TM sweat patch. Patches were removed at specified times over 1 week, and the drug content was determined by gas chromatography-mass spectrometry using deuterated internal standards. Codeine was detectable at 1 h following the administration, and a plateau concentration was observed on the third day. The peak codeine concentration was observed during the 12-24-h period. Morphine was never detected in sweat. In contrast, phenobarbital was first observed 3 h after administration, and cumulative excretion was continual throughout the week. Intersubject variability was enormous, as the concentrations for the same dose were in a magnitude of 1-5. Concentrations were in the range of 2-127 and 0.5-33 ng per patch for codeine and phenobarbital, respectively. The influence of the site of patch application was evaluated by analysis of six patches, all removed at the same time (24 h) in two subjects receiving 90 mg codeine. Codeine concentrations differed by a magnitude of 1-3 according to the area of application: the upper arm, the back, and the ribs. These data suggest that the sweat patch technology can be useful for documenting drug use over a 1-week period of surveillance.
Introduction
The presence of drugs of abuse in the body is identified by a variety of well-established procedures. The standard in drug testing has been the immunoassay screen, followed by the gas chromatographic-mass spectrometric (GC-MS) confirmation conducted on a urine sample.
More recently, a variety of body fluids and tissues other than urine, such as saliva (1) and hair (2) , have been proposed to 9 Author to whom correspondence should be addressed. document drug exposure. Hair testing is generally presented to complement blood and urine analyses, which yield information about the presence of drug at a single point in time. However, hair does not appear to be a suitable specimen for monitoring exposure on a weekly basis.
Researchers (3) have known since 1911 that drugs are excreted by the body in sweat, but until recently, no one has been able to develop a practical solution to the problem of capturing sweat before testing. An occlusive bandage consisting of one to three layers of filter paper (4) or pieces of cotton, gauze, or towel (5) were previously proposed to collect sweat. By using these homemade collectors, it was possible to identify various drugs, including quinine, salicylic acid, antipyrine (3), ethanol (6) , methadone (7), phenobarbital (8), morphine (5), cocaine (9), cannabis (10), methamphetamine (11) , and phencyclidine (12) . More recently, clothes were shown to retain opiates excreted in sweat (13) , which led us to conclude that it is therefore possible to obtain evidence about the drug abuser status of the owners of the pieces of garment (underwear).
Significant advances have been made during the past years to develop a sweat patch technology, which was recently proposed by Pharmchem TM Laboratories (Menlo Park, CA) (14) . The sweat patch acts as a specimen container for nonvolatile and liquid components of sweat, including drugs of abuse. Sweat components are collected on a special absorbent pad, located in the center of the patch. Nonvolatile substances from the environment cannot penetrate the transparent film, which is a semipermeable membrane over the pad that allows oxygen, water, and carbon dioxide to pass through the patch, leaving the skin underneath healthy. Over a period of several days, sweat saturates the pad and slowly concentrates it; drugs present in sweat are retained. A unique number is imprinted on each patch to aid with chain of custody and identification.
To date, few applications of the sweat patch have been described; all of them have involved detection of drugs of abuse, including heroin (15) , cocaine (15) (16) (17) , phencyclidine (18) , and tetrahydrocannabinol (19) . This report describes a series of sweat excretion experiments with subjects who were receiving single doses of codeine or phenobarbital.
Experimental

Chemicals and material
Methanol, isopropanol, n-heptane, n-hexane, diethylether, and chloroform were high-performance liquid chromatographic grade (Merck, Darmstadt, Germany). All other chemicals were analytical grade and were provided by Merck.
Codeine phosphate and phenobarbital were obtained from Francopia (Paris, France) and Specia (Paris, France), respectively. Morphine-d3, codeine-d3, and phenobarbital-ds were purchased from Radian (Austin, TX).
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) plus i% trimethyl chlor.osilane (TMCS) was purchased from Interchim (Montlu(/on, France). Trimethyl phenylammonium hydroxide in methanol (Barb-Prep) was purchased from Alltech (Deerfield, IL).
GC-MS method
The GC-MS system consisted of a Hewlett-Packard (5890 series II) chromatograph with a mass selective detector and a 5989B MS engine, which was operated at 70 eV with an ion source temperature of 250~ The electron multiplier voltage was set at +400 V above autotune voltage. The MS engine was autotuned daily with perfluorotributylamine. The carrier gas was helium (purity, N55), and the flow through the HP-5 MS capillary column (5% phenyl-95% methyl siloxane; 30 m x 0.25-ram i.d.) was 1.0 mL/min.
The column oven temperature was programmed from an initial temperature.of 60~ to 290~ at 30~ the temperature was maintained at 290~ for the final 5 min. Splitless injection with a split value off-time of 0.75 min was employed. The injector temperature was 260~ The ions monitored and typical retention times (t~) of the different analytes and the deuterated internal standards were as follows: codeine and codeine-d3, rn/z 371 and 374, respectively (tR, 9.55 rain); morphine and morphine-d3, m/z 429 and 432, respectively (tn, 9.71 min); and phenobarbital and phenobarbital-ds, m/z 232 and 237, respectively (tR, 7.56 rain). Drugs were identified and quantitated based on comparison of retention times and relative abundance of two confirming ions to the deuterated internal standards.
Subjects
Subjects were recruited from the laboratory personnel. All denied use of codeine or phenobarbital during the 3 previous months. The week before enrollment, two urine tests were performed; the results were negative. Subjects agreed to abstain from pharmaceuticals and alcohol during the study. Six males (aged 24-33 years) and two females (both aged 33 years) participated in the protocol. They signed an informed consent agreement and were paid for participation. They were encouraged to continue their normal hygiene practices.
Sweat patches were provided by Pharmchem Laboratories.
Sweat collection
Sweat patches were applied to the outer portion of the upper arm or back. The selected skin site for patch placement was gently cleansed with a 70% isopropanol swab before application. The study protocol, along with the number of applied patches and time of removal, is presented in Table I .
Drugs were orally administered by solubilization in 100 mL water. The six males received 90 mg codeine phosphate, whereas the two females received 100 mg phenobarbital During the cumulative excretion experiments, a urine sample was collected each time a patch was removed. After removal of the patch, the absorption pad was stored in a plastic tube at -20~
Analytical procedure
The absorbent pads were placed in extraction tubes, and 2. 
Results
Analytical procedure
Standard curves were constructed for each drug by addition of known concentrations (1, 2, 5, 10, 50, 100, and 200 ng) of drug and internal standard (200 ng) to drug-free absorption pads. The assay was linear for concentrations in the range tested, and correlation coefficients of 0.997 and 0.996 for codeine and phenobarbital, respectively, were found. The extraction recoveries were 94.2 and 93.1% for codeine and phenobarbital, respectively. Within-run and between-run coefficients of variation were less than 12% for both drugs. The limits of detection for codeine and phenobarbital were approximately 0.5 ng per patch, and the signal-to-noise ratio was 3. Figure 1 illustrates the selected-ion monitoring responses for codeine and codeine-d3. Under the chromatographic conditions used, there was no interference with the target compounds by any extractable endogenous materials present in sweat. 
Cumulative excretion of codeine
Patches were applied prior to drug administration and removed periodically over a period of 7 days. The analysis of the patches is presented Table II . An increase of codeine concentration was constant during the first 48-72 h, where a plateau was observed. The maximum codeine concentration varied by a factor of 5 among the three subjects. This could be due to the variation in perspiration rates between individuals. Nevertheless, the pattern of codeine excretion in the sweat patches was similar for the three subjects. Morphine, a metabolite of codeine, was never detected in the sweat patches (limit of detection for morphine, 0.5 ng per patch). Codeine and morphine were detected in the first urine sample and remained positive until day 4 ( Table III) . The codeine-tomorphine ratio was greater than I during i the first 12 h and then decreased to 0.10; 1 morphine was then the major analyte. Time course of excretion of codeine in sweat The time course of appearance of codeine in sweat was evaluated by application of sweat patches in incremental time sequences following 90 mg oral administration. The results are presented in Table IV .
Codeine appeared in sweat within 1 h after drug administration, which was con* sistent with the first experiments of this study. The concentration peaked at 12-24 h, and a second increase of codeine concentration was observed at 72-98 h, which must be confirmed by other investigations. Again, morphine was not detected.
Influence of the site of patch application
To evaluate the influence of the site on the body for patch application, three areas were selected (i.e., the upper arm, the upper back, and the chest along the lateral rib). Patches were placed to the left and to the right of the three areas on the two subjects receiving a single oral codeine dose of 90 mg. Patches were removed after a 24-h application. The results are listed in Table  V . According to the site of application, concentrations differed by as much as threefold. In one subject, maximal concentrations were observed after rib application, whereas the back application exhibited maximal concentrations in the second subject. There were also some discriminations between left and right sites. This probably indicates that the patch cannot be used to quantitate the amount of drug consumed and that this technology is still more of a qualitative test.
Cumulative excretion of phenobarbital
Patches collected after a single, 100 mg oral dose of phenobarbital were analyzed by GC-MS. The analysis of the patches is shown in patch is the time of detection for drugs. For urine testing, the window of detection for drugs of abuse, especially when considering the immunoassay cut-offs, is approximately 1-3 days after the last use of the drug, with the exception of cannabis. The sweat patch can be worn for at least 7 days, and therefore, sweat testing appears to offer the adv,~ntage of being a noninvasive means of obtaining an estimate of drug exposure over a period of several days. This new technology is complementary to urine and hair investigations. Hair can be used to monitor drug use for weeks to months back in time but appears not to be suitable for shorter periods. Moreover, sweat can evidence single drug use, as reported by other investigators (15) (16) (17) (18) (19) . Most studies in the literature have focused on cocaine, which was detectable in trace amounts following the administration of 1 mg of drug (15) . For cocaine, concentrations in sweat peaked at 2-4 h; this differed for codeine and phenobarbital, probably because of the different half-life of the drugs as well as their lipid solubility, as the passive diffusion from blood to sweat is probably more favorable for basic substances (20) .
Excretion in sweat appears to be maximal, and basic drugs have high partition coefficients and PKa values close to the value of sweat (pH 4-6.8). This phenomenon suggests that the 1  6310  6214  3  1710  5309  12  2538  4546  24  2751  3763  36  3184  3955  48  3456  2243  72  2221  3050  96  1664  1718  120  2150  2219  144  1637  1773 excretion rate of basic drugs strongly relates with a drug's membrane permeability, based on the pH gradient between blood (pH 7.4) and sweat (more acidic). The same observations were noted on the incorporation rates of drugs into hair, an acidic matrix of pH less than 5 (2] ).
[t appears that sweat and hair are connected because drugs in sweat could be the primary means by which drugs of abuse are sequestered in hair (22) .
In conclusion, sweat testing is a new technology suitable to extend the window of drug detection, particularly in the treatment and monitoring of substance abusers.
